Cancer research · Clinical trials
Earlier Signals, Smarter Decisions: MRD
Measurable residual disease (MRD) assays may detect traces of cancer after therapy and help researchers study treatment response earlier. The reliability and use of MRD endpoints vary by disease and assay.
Measurable residual disease tests seek evidence of malignant cells or molecular markers after treatment, at levels below conventional clinical detection.
Assay sensitivity, specificity and clinical validity vary across cancers. Whether acting on an MRD result improves outcomes requires disease-specific evidence.
AI-assisted preliminary overview · Awaiting editorial review. The linked materials are research leads; some citations remain to be checked against the original works.